Lexaria Bioscience Corp. Common Stock (LEXX) Stock Price

LEXXStock

$11.60−11.43%52W

Market Cap$19.17M

P/E—

PEG Ratio—

Div yield—

Beta0.49

LEXX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-4.78%

Price vs S&P 500 (4W)27.07%

VGM Score39.85

Book Value / Share (Quarterly)$2.87

P/TBV (Annual)6.42x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)39.51%

Cash Flow / Share (Quarterly)$-4.64

Price vs S&P 500 (YTD)1.99%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-2156.23%

EPS (TTM)$-3.35

10-Day Avg Trading Volume0.04M

EPS Excl Extra (TTM)$-3.35

Revenue Growth (5Y)17.89%

EPS (Annual)$-9.92

ROI (Annual)-398.09%

Gross Margin (Annual)99.61%

Net Profit Margin (5Y Avg)-1837.15%

Cash / Share (Quarterly)$2.19

Revenue Growth QoQ (YoY)-88.51%

ROA (Last FY)-285.07%

Revenue Growth TTM (YoY)-68.50%

EBITD / Share (TTM)$-1.26

ROE (5Y Avg)-162.22%

Operating Margin (TTM)-2157.06%

Cash Flow / Share (Annual)$-8.20

P/B Ratio2.83x

P/B Ratio (Quarterly)3.22x

Net Income / Employee (Annual)$-1,700,300

EV / Revenue (TTM)26.93x

ROA (TTM)-143.89%

EV / EBITDA (TTM)122.04x

EPS Incl Extra (Annual)$-9.92

Current Ratio (Annual)2.32x

Quick Ratio (Quarterly)9.56x

3-Month Avg Trading Volume0.01M

52-Week Price Return-11.43%

Revenue / Employee (TTM)$27,700

Tangible BV / Share (Quarterly)$2.66

P/S Ratio (Annual)18.96x

Asset Turnover (Annual)0.17x

52-Week High$23.25

Operating Margin (5Y Avg)-1896.92%

EPS Excl Extra (Annual)$-9.92

CapEx CAGR (5Y)51.95%

Tangible BV CAGR (5Y)3.67%

26-Week Price Return6.46%

Quick Ratio (Annual)1.56x

13-Week Price Return16.08%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)10.60x

Enterprise Value$9.91M

Revenue / Share Growth (5Y)39.37%

Asset Turnover (TTM)0.06x

Book Value / Share Growth (5Y)22.14%

Revenue / Employee (Annual)$100,800

Inventory Turnover (Annual)1.50x

Pretax Margin (Annual)-1687.36%

Cash / Share (Annual)$1.51

3-Month Return Std Dev128.63%

Gross Margin (5Y Avg)85.36%

Net Income / Employee (TTM)$-1,104,600

ROE (Last FY)-398.09%

EPS Basic Excl Extra (Annual)$-9.92

P/FCF (TTM)58.20x

Receivables Turnover (TTM)4.54x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-3.35

Receivables Turnover (Annual)4.54x

ROI (TTM)-160.72%

P/S Ratio (TTM)36.37x

Pretax Margin (5Y Avg)-1896.92%

Revenue / Share (Annual)$0.59

Tangible BV / Share (Annual)$2.06

Price vs S&P 500 (52W)-29.74%

Year-to-Date Return13.95%

5-Day Price Return-8.51%

EPS Normalized (Annual)$-9.92

ROA (5Y Avg)-137.97%

Net Profit Margin (Annual)-1686.00%

Month-to-Date Return79.56%

Cash Flow / Share (TTM)$-1.13

EBITD / Share (Annual)$-9.85

Operating Margin (Annual)-1687.36%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-162.22%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-3.35

P/TBV (Quarterly)3.47x

P/B Ratio (Annual)5.76x

Inventory Turnover (TTM)1.50x

Pretax Margin (TTM)-2157.06%

Book Value / Share (Annual)$2.29

Price vs S&P 500 (13W)13.29%

Beta0.49x

P/FCF (Annual)58.20x

Revenue / Share (TTM)$0.12

ROE (TTM)-160.72%

52-Week Low$4.21

vGradeD

gGradeD

mGradeB

vgmGradeD

LEXX Earnings Surprise History

Q3 25-1.95est. -2.35

Q4 25-1.05est. -1.95

Q1 26-0.90est. -1.05

Q2 26-1.20est. -0.90

LEXX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
LEXXLexaria Bioscience Corp. Common Stock	D	D	B	$11.60
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Lexaria Bioscience Corp. Common Stock

Lexaria Bioscience is a biotechnology company that generates revenue by licensing its proprietary DehydraTECH drug delivery technology, which enhances the bioavailability and effectiveness of active pharmaceutical ingredients. The platform has broad applicability across therapeutics including GLP-1 drugs, pain medications, cannabinoids, and more, serving disease areas like diabetes, weight loss, and hypertension. DehydraTECH can be incorporated into multiple product formats—tablets, capsules, beverages, and foods—for use in pharmaceuticals, nutraceuticals, and consumer products.